BioVie showcases Long COVID and Parkinson’s data at ANA2026, with findings in Annals of Neurology

Podcast: Proactive - Interviews for investors · Proactive

Opublikowano: 2026-10-21

BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) CEO Cuong Do joined Proactive's Stephen Gunnion after the company presented findings from its Long COVID and Parkinson’s disease trials at the American Neurological Association’s Annual Meeting in San Diego. The Long COVID study findings were published in the peer-reviewed journal Annals of Neurology, alongside the meeting. In the ADDRESS-LC Long COVID study, BioVie reported statistically significant improvements in pre-specified subgroups of patients with a high burden of symptoms, including fatigue, cognitive impairment and post-exertional malaise. Do discusses the findings on brain fog and fatigue, and the case for a confirmatory Phase 3 tria...